Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orthofix won't sell fixation lines, looks to strengthen ortho unit instead:

This article was originally published in Clinica

Executive Summary

Orthofix International said it is holding on to its external and internal bone fixation products, less than two months after announcing it was looking for buyers for the business. Instead, the company said it will look to free up more cash by tightening operating costs and maximising the value of its orthopaedic business. Growth in Orthofix's orthopaedics business in 2007 was stymied by declining sales of external fixation devices, which fell 11%. Internal fixation sales, on the other hand, soared 48%, aided by the introduction of new products. Orthofix, headquartered in the Netherlands, had announced in February that it was looking to sell its orthopaedic fixation products to reduce debt and invest in its core spine business.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel